Cargando…
Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711028/ https://www.ncbi.nlm.nih.gov/pubmed/31357896 http://dx.doi.org/10.1080/10717544.2019.1642420 |
_version_ | 1783446453601959936 |
---|---|
author | Khan, Muhammad Muzamil Madni, Asadullah Torchilin, Vladimir Filipczak, Nina Pan, Jiayi Tahir, Nayab Shah, Hassan |
author_facet | Khan, Muhammad Muzamil Madni, Asadullah Torchilin, Vladimir Filipczak, Nina Pan, Jiayi Tahir, Nayab Shah, Hassan |
author_sort | Khan, Muhammad Muzamil |
collection | PubMed |
description | Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chitosan hybrid nanoparticles were formulated by the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid. Formulations with various chitosan to lipid ratios were investigated to obtain the optimal particle size, encapsulation efficiency, and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a size range of 181–245 nm and a zeta potential range of 20–30 mV. The stability of the formulation was demonstrated by thermal studies. Cytotoxicity and cellular interaction of cisplatin-loaded LPHNP were investigated using in vitro cell-based assays using the A2780 ovarian carcinoma cell line. The pharmacokinetics study in rabbits supported a controlled delivery of cisplatin with enhanced mean residence time and half-life. These studies suggest that cisplatin loaded LPHNP have promise as a platform for controlled delivery of cisplatin in cancer therapy. |
format | Online Article Text |
id | pubmed-6711028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-67110282019-09-05 Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin Khan, Muhammad Muzamil Madni, Asadullah Torchilin, Vladimir Filipczak, Nina Pan, Jiayi Tahir, Nayab Shah, Hassan Drug Deliv Research Article Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chitosan hybrid nanoparticles were formulated by the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid. Formulations with various chitosan to lipid ratios were investigated to obtain the optimal particle size, encapsulation efficiency, and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a size range of 181–245 nm and a zeta potential range of 20–30 mV. The stability of the formulation was demonstrated by thermal studies. Cytotoxicity and cellular interaction of cisplatin-loaded LPHNP were investigated using in vitro cell-based assays using the A2780 ovarian carcinoma cell line. The pharmacokinetics study in rabbits supported a controlled delivery of cisplatin with enhanced mean residence time and half-life. These studies suggest that cisplatin loaded LPHNP have promise as a platform for controlled delivery of cisplatin in cancer therapy. Taylor & Francis 2019-07-29 /pmc/articles/PMC6711028/ /pubmed/31357896 http://dx.doi.org/10.1080/10717544.2019.1642420 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Khan, Muhammad Muzamil Madni, Asadullah Torchilin, Vladimir Filipczak, Nina Pan, Jiayi Tahir, Nayab Shah, Hassan Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin |
title | Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin |
title_full | Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin |
title_fullStr | Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin |
title_full_unstemmed | Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin |
title_short | Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin |
title_sort | lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711028/ https://www.ncbi.nlm.nih.gov/pubmed/31357896 http://dx.doi.org/10.1080/10717544.2019.1642420 |
work_keys_str_mv | AT khanmuhammadmuzamil lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin AT madniasadullah lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin AT torchilinvladimir lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin AT filipczaknina lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin AT panjiayi lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin AT tahirnayab lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin AT shahhassan lipidchitosanhybridnanoparticlesforcontrolleddeliveryofcisplatin |